There is no cure for any type of Ehlers-Danlos syndrome (EDS). EDS is a group of 13 inherited conditions that affect connective tissue, and they differ a lot. The one with the most research progress is vascular EDS (vEDS), where a beta-blocker called celiprolol is in a Phase 3 U.S. trial. Most other types are managed with physical therapy, joint protection and pain care. Our view: gene-level fixes are far off, and the nearest gains are better diagnosis, a proven vEDS drug, and clearer care pathways.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Care decisions belong with a doctor experienced in EDS.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your doctor experienced in EDS.
In vascular EDS caused by a change that makes abnormal collagen, could a drug that silences only the faulty COL3A1 copy (a drug that does not yet exist for people) shift the disease toward the milder null form? It could be tested first in vEDS mice and patient-derived artery cells. The null form still carries artery risk, so success would mean milder disease, not a cure.
What would prove it wrong: if silencing the faulty copy in vEDS mice does not reduce aortic ruptures.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
In a review of records of 81 people with hypermobile EDS or hypermobility spectrum disorder sent to one Israeli gut clinic, constipation (65%), bloating (61%) and abdominal pain (68%) were common, and 63% met criteria for irritable bowel syndrome. Tests often found slowed sensation in the rectum and structural problems such as rectocele. The authors call for symptom-based gut testing. A single-center, retrospective study.
In 60 people with vascular EDS (COL3A1 variants) who had 105 catheter procedures through the groin artery, major access complications happened in 5 of 39 sites sealed with closure devices and in none of 33 sites closed by manual pressure. No complications followed planned open surgical exposure. The authors say access needs individual planning. A retrospective study, not a trial.
A review says people with hypermobility spectrum disorder or hypermobile EDS, especially with mast cell activation syndrome or dysautonomia, may face a higher risk of problems with surgery, anesthesia, medicines and infections. The authors call for larger long-term studies. A review of limited evidence, not a new trial.
A review of the evidence found it is low-level and does not support any drug as effective for pain from hypermobility, whether disease-specific, repurposed or new. The author says medicine alone may help occasional pain flares, but long-lasting pain usually needs a mix of approaches, with one drug at a time, a low dose and a planned check of benefit and side effects. A review, not a new trial.
The Ehlers-Danlos Society plans to publish a review and update of the classification for all EDS types and hypermobility spectrum disorders, followed by a clinician diagnostic guide in March 2027.
Among 100 patients from one hypermobility clinic, 55.6% (55 of 99) reported a lifetime fracture, but only two were in infancy and the pattern matched typical childhood fractures. The authors found no clear sign of fragility fractures in non-ambulatory children. Small, single-clinic, based on recall.
Researchers described 93 people with this rare type. More than 70% had weak muscle tone, and up to 26% had blood-vessel events, often at a young age. Lab tests on patient skin cells showed how the faulty enzyme disturbs collagen. This improves understanding; it is not a treatment.
Ten people with hypermobile EDS got up to four infusions of a substance made from donor stem cells. No treatment-related side effects were reported. Six of ten reported clear symptom improvement, but all five who stopped treatment and were followed went back to their earlier symptoms. There was no placebo group, symptoms were self-reported on a custom questionnaire, and it is not proof the treatment works.
A feasibility study testing a structured program for adults with vascular EDS.
A Japanese cohort study reported clinical outcomes and patient experiences with celiprolol. It was generally well tolerated and appeared to reduce life-threatening vascular complications.
A randomized, double-blind, decentralized trial in about 150 people aged 15 and older with a confirmed COL3A1 variant, measuring time to a medical emergency. The FDA recognizes the design could support an approval application.
In 57 adults with vEDS already taking celiprolol, irbesartan reduced severe arterial events by about 50% over two years versus placebo.
Researchers found a shared extracellular-matrix fragmentation pattern in plasma from patients, which could someday help diagnosis.
A review of the available evidence on celiprolol for reducing vascular events in vEDS.
No drug is approved for any type of EDS. Care aims to protect joints, manage pain, and, in vascular EDS, reduce the risk of artery rupture.
A beta-blocker that also relaxes blood vessels. A 2010 French trial found about a two-thirds lower rate of arterial events. The FDA has granted Breakthrough Therapy and orphan designations. A 2026 study of the first non-European cohort found it generally well tolerated.
Adding irbesartan to celiprolol roughly halved severe arterial events over two years, a promising result that needs confirmation in a larger study.
Strengthening exercises that stabilize loose joints are the core of care for hEDS. A feasibility study of an exercise and lifestyle program for adults with vEDS is also registered.
Pacing, bracing, heat, and carefully chosen medicines. Because many people have chronic pain, specialist pain clinics are often part of care.
Tissue is fragile, so surgery is approached with caution, especially in vEDS, and is done by teams who know the condition.
A confirmed gene change identifies the type and, for vEDS, guides life-saving monitoring. hEDS has no gene test yet.
| Treatment | For | What it does |
|---|---|---|
| Physical therapy & joint protection | Hypermobile, classical and others | Builds stability and reduces dislocations and injury. |
| Pain care | Most types | Combines pacing, therapy, and medicines to ease chronic pain. |
| Beta-blocker (often celiprolol where available) | Vascular EDS | Lowers stress on fragile arteries. Celiprolol is not FDA-approved in the U.S. |
| Vascular imaging & emergency plan | Vascular EDS | Specialist monitoring and a clear plan for sudden severe pain. |
| Wound care | Classical and others | Gentle closure techniques for fragile skin. |
No supplement fixes faulty collagen. Daily habits that protect joints and manage symptoms help most. We rate each by the strength of evidence.
Supervised, low-impact strengthening helps stabilize loose joints.
Splints, bracing and avoiding end-range stretching are widely used by therapists.
Gentle handling and protecting fragile skin reduces tears and bruising.
No evidence they fix genetic collagen faults.
Can injure loose joints. Seek therapists who know hypermobility.
FDA safety communications link this class to aortic aneurysm and dissection. People with vascular EDS should discuss this with their doctor.
Be careful: people with vascular EDS should carry an emergency card, know their type, and seek emergency care for sudden severe pain in the chest, abdomen, head or neck.
Centers recognized for expertise in this condition, and communities of people living with it.
Part of The Ehlers-Danlos Society's Centers and Networks of Excellence program, designated in 2023.
Part of The Ehlers-Danlos Society's Centers and Networks of Excellence program, designated in 2023.
Part of The Ehlers-Danlos Society's Centers and Networks of Excellence program, designated in 2023.
Part of The Ehlers-Danlos Society's Centers and Networks of Excellence program, designated in 2023.
Named to The Ehlers-Danlos Society's Centers and Networks of Excellence program in its second cohort.
Named to The Ehlers-Danlos Society's Centers and Networks of Excellence program in its third cohort.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
Living with EDS can be isolating, and others who understand can help. Most of these are free.
The main international patient organization, with information, research updates and support resources.
Visit ↗The UK charity offering information, a helpline and local groups.
Get support ↗An online community where patients and caregivers share experiences.
Join ↗Many private patient groups exist, including ones for each type. This link searches Facebook (a login is required).
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Protect your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
No country has approved a drug for EDS. Where celiprolol is sold, notably France, it is used for vascular EDS, which is why the evidence came from there.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Drug approved for EDSSpecific indication | None | None | None | None | None | None | None | None | None |
| Celiprolol for vEDSOff-label or in trial | Phase 3 | Used (France) | — | — | Cohort data | — | — | — | — |
The trial that found celiprolol lowered arterial events in vEDS was run in France, and French centers have the most experience with the drug.
A Japanese cohort reported celiprolol outcomes and patient experiences in the first study of its kind outside Europe.
An international effort is rewriting the classification and diagnostic criteria, with publication planned for December 2026.
EDS is a family of inherited conditions in which collagen and related proteins, the "glue" and scaffolding of skin, joints, blood vessels and organs, are faulty. There are 13 recognized types. Genes are known for 12 of them. The most common, hypermobile EDS, has no known gene.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
This organization helps people affected by Ehlers-Danlos syndromes pay for care and costs. Funds are limited and rules vary, so contact it directly.
The UK charity's grants toward treatments, therapies, medical equipment and aids, and travel and lodging for medical care. A referral or recommendation from a registered practitioner is needed. There's no set amount, and grants are usually only part of the cost. Grants open in rounds; the round open on October 6, 2026 closes October 16, 2026.
See the grant ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 2, 2026.
The 2010 Lancet figure for celiprolol (about a two-thirds lower rate of events), the 2017 classification date and 13-type count, the fluoroquinolone caution, and the specific Japanese-cohort conclusions are taken from the cited reviews and news coverage, with the 2010 trial and 2017 consensus not individually linked here. The "—" cells in the approvals table mean not verified. Financial help: checked October 6, 2026. Only one qualifying organization was found, and it is UK-only. The Ehlers-Danlos Society, Ehlers-Danlos Support UK and Annabelle's Challenge were left out because their pages describe no grants to individuals; an Orange County EDS Charitable Fund was left out because its page could not be read.